On April 22, 2004, King, Bryan W.; Sheppeck, James; Gilmore, John L. published a patent.Recommanded Product: 362703-57-9 The title of the patent was Preparation of triazolone and triazolethione inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme as anti-inflammatory agents. And the patent contained the following:
The present application describes novel hydantoin derivatives (shown as I; A = O, S; L-R11 represents a very large variety of substituents and is defined in the claims; e.g. II) or pharmaceutically acceptable salt or prodrug forms thereof, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), aggrecanase, or a combination thereof. Some examples of I exhibit Ki’s <10 μM but individual data are not presented. Although the methods of preparation are not claimed, 37 example preparations are included. For example, II was prepared in 4 steps (100, 66, 73 and 82%, resp.) starting with condensation of Et 4-aminobutyrate hydrochloride with 4-(2-methylquinolin-4-ylmethoxy)benzoyl chloride hydrochloride followed by base hydrolysis to the acid, followed by hydrazide formation with thiosemicarbazide followed by cyclization. The experimental process involved the reaction of tert-Butyl 4-amino-4-(2-methoxy-2-oxoethyl)piperidine-1-carboxylate(cas: 362703-57-9).Recommanded Product: 362703-57-9
The Article related to triazolone triazolethione preparation inhibitor matrix metalloproteinase tace antiinflammatory, tnf alpha converting enzyme inhibitor triazolone triazolethione preparation, aggrecanase inhibitor triazolone triazolethione preparation and other aspects.Recommanded Product: 362703-57-9
Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem